Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Revista
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Lupus ; 30(4): 597-607, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-33413005

RESUMEN

Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease. Patients diagnosed with juvenile-onset SLE (jSLE), when compared to individuals with adult-onset SLE, develop more severe organ involvement, increased disease activity and greater tissue and organ damage. In adult-onset SLE, clinical characteristics, pathomechanisms, disease progression and outcomes do not only vary between individuals and age groups, but also ethnicities. However, in children and young people, the influence of ethnicity on disease onset, phenotype and outcome has not been investigated in detail. In this study, we investigated clinical and laboratory characteristics in pediatric SLE patients from different ethnic backgrounds (White Caucasian, Asian, Black African/Caribbean) accessing data from a national cohort of jSLE patients (the UK JSLE Cohort Study). Among jSLE patients in the UK, ethnicity affects both the disease's clinical course and outcomes. At diagnosis, Black African/Caribbean jSLE patients show more "classical" laboratory and clinical features when compared to White Caucasian or Asian patients. Black African/Caribbean jSLE patients exhibit more renal involvement and more frequently receive cyclophosphamide and rituximab. Studies targeting ethnicity-specific contributors to disease expression and phenotypes are necessary to improve our pathophysiological understanding, diagnosis and treatment of jSLE.


Asunto(s)
Etnicidad/estadística & datos numéricos , Laboratorios/estadística & datos numéricos , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/etnología , Nefritis Lúpica/tratamiento farmacológico , Adolescente , Edad de Inicio , Niño , Estudios de Cohortes , Ciclofosfamida/uso terapéutico , Progresión de la Enfermedad , Quimioterapia Combinada , Femenino , Estudios de Seguimiento , Humanos , Factores Inmunológicos/uso terapéutico , Inmunosupresores/uso terapéutico , Lupus Eritematoso Sistémico/tratamiento farmacológico , Lupus Eritematoso Sistémico/inmunología , Nefritis Lúpica/complicaciones , Nefritis Lúpica/etnología , Nefritis Lúpica/fisiopatología , Masculino , Fenotipo , Rituximab/uso terapéutico , Índice de Severidad de la Enfermedad , Reino Unido/etnología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA